A2 Bio Stock
HealthTechLooking to sell A2 Bio stock or options?
A2 Bio is the developer of a cell therapy aimed at curing cancer through precise tumor targeting. The company creates engineered tumor cells that focus on the genetic material deficiencies in tumors, selectively destroying tumor cells while sparing normal ones. This innovative approach allows physicians to transform the treatment of solid tumors.
BCM Ventures, Casdin Capital, S32, Hartford Healthcare Endowment, Mana Ventures, C/O Uc San Francisco, Samsara BioCapital, Euclidean Capital, Merck & Co., Vida Ventures (Boston), UC Investments, StepStone Group, Schroders, The Column Group, Nextech Invest.
Collective explained in 2 minutes
Learn how Collective's solutions enable you to manage your risk and maximize your wealth
Our available services for this company
Management Team
Board Members
A2 Bio’s stock FAQs
A2 Bio is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize A2 Bio stock. Depending on A2 Bio’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange A2 Bio stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of A2 Bio stock in two ways. First, A2 Bio employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your A2 Bio stock. Note that all transactions in A2 Bio shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
A2 Bio stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for A2 Bio stock. Typically, shares of private companies like A2 Bio are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Nov 2022, A2 Bio is reported to have closed an equity financing in which the investors valued the company at $397M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of A2 Bio shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because A2 Bio is not currently publicly traded, it does not have a ticker symbol.
A2 Bio has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though A2 Bio is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on A2 Bio shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
